Microbiota
Conditions
Keywords
gut microbiota, 16S rRNA gene, Graves' disease, Methimazole, Propylthiouracil
Brief summary
Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls and analyse the relationship between intestinal microbiota and GD drug therapy.
Detailed description
Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls before and found that gut microbiota changed between GD patients and healthy controls.But there are few articles on the relationship between intestinal microbiota and drug treatment of GD, so Investigators explored the relationship between intestinal microflora and methimazole treatment for GD.
Interventions
DRUGMethimazole Pill
Patients who developed GD received methimazole treatment
Patients who developed GD received propylthiouracil treatment
Sponsors
First Affiliated Hospital of Harbin Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 18 to 65 years * GD was clinical diagnosed and accept the standard treatment of methimazole or propylthiouracil and thyroid function returned to normal
Exclusion criteria
* Pregnancy * Lactation * Cigarette smoking * Alcohol addiction * Hypertension * Diabetes mellitus * Lipid dysregulation * BMI \> 27 * Recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine * History of disease with an autoimmune component, such as MS, rheumatoid arthritis, IBS, or IBD * History of malignancy or any gastrointestinal tract surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptional changes in gut microbiota | Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal | The microbiota measured by 16S rRNA gene |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum thyroid function changed | Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal | Serum thyroid function measured by Immunohistochemistry |
Other
| Measure | Time frame | Description |
|---|---|---|
| Serum thyroid related antibodies changed | Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal | Serum thyroid related antibodies measured by Immunohistochemistry |
Countries
China
Contacts
Primary ContactYunwei Wei
Outcome results
None listed